Development of recombinant rsolCD39-PSGL as a novel therapeutic with anti-thrombotic and anti-inflammatory effects

重组rsolCD39-PSGL作为具有抗血栓和抗炎作用的新型治疗剂的开发

• 批准号: nhmrc : 520697
• 负责人: Prof Anthony D'Apice
• 金额: $ 12.43万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-recombinant-rsolcd39-inflammatory-effects/94662
• 关键词: Development; recombinant; rsolCD39; PSGL; novel

Heart disease and stroke are due to a narrowing of arteries followed by occlusion, due a combination of clot formation initiated by platelet clumping, and inflammation surrounding the vessel wall. The currently available drugs are often limited by the adverse reaction of bleeding. We will investigate the efficiency of a new drug to prevent clot formation and inflammation.

心脏病和中风是由于动脉狭窄随后闭塞，由于血小板聚集引发的凝块形成和血管壁周围炎症的组合。目前可用的药物往往受到出血不良反应的限制。我们将研究一种新药预防血栓形成和炎症的有效性。